Browse 122 retinitis pigmentosa clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Retinitis pigmentosa usually begins with trouble seeing at night and slowly narrows side vision, and more than 100 genes have been linked to it. The eye was the site of a medical first: in 2017 the FDA approved its first gene therapy for an inherited disease, for vision loss caused by one of those genes. Most people with retinitis pigmentosa have a different gene change and still no approved treatment. Gene therapies, cell therapies, and treatments that work regardless of the gene are now in trials, and genetic testing is the first step toward them.
Location: Boston MA, Philadelphia PA, Baltimore MD, Durham NC,
Sponsor: Jaeb Center for Health Research
Sex: All
Age: 4+
Code: NCT05589714
Recruiting
Active & Responsive
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
for
Retinitis Pigmentosa (RP), Usher Syndrome
Location: Dallas TX
Sponsor: Nacuity Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT07710196
Phase 3, Recruiting
Active & Responsive
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
for
Retinitis Pigmentosa
Location: Dallas TX, Portland OR
Sponsor: Octant, Inc.
Sex: All
Age: 18+
Code: NCT07408232
Phase 1, Phase 2, Recruiting
Active & Responsive
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)